(CercleFinance.com) – Innate Pharma announces that new results from a phase 1/2 dose escalation study with SAR’579, resulting from a collaboration with Sanofi, were presented this Sunday at the annual congress of the European Hematology Association (EHA) 2024 in Madrid.
This drug candidate, the most advanced on its ANKET platform, continues to show clinical benefit, durable responses as well as a favorable safety profile in patients with relapsed/refractory acute myeloid leukemia (R/R AML) .
As a reminder, this study led by Sanofi evaluates this NK cell as a monotherapy in hematological cancers with high medical need, including R/R AML, B-cell acute lymphoblastic leukemia or high-risk myelodysplastic syndrome.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
